Evidence map›Paper›PMID 27536664›Full record

ReviewKidney diseases (Basel, Switzerland)2015

Genetics and Epigenetics of Diabetic Nephropathy.

Ruijie Liu, Kyung Lee, John Cijiang He

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney diseases (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Epigenetic modification in diabetic kidney disease.Frontiers in endocrinology · 2023
    Review
  6. miRNAs as Biomarkers in Diabetes: Moving towards Precision Medicine.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Comparative Morphological, Metabolic and Transcriptome Analyses inFrontiers in cell and developmental biology · 2022
    Article
  9. Article
  10. Article
  11. Epigenetic Regulations in Diabetic Nephropathy.Journal of diabetes research · 2017
    Review
  12. Review
  13. East Meets West: Harmony but Not Uniformity.Kidney diseases (Basel, Switzerland) · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ruijie LiuDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA; Renal Section, James J. Peters VAMC, New York, N.Y., USA.
Kyung LeeDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA.
John Cijiang HeDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA; Renal Section, James J. Peters VAMC, New York, N.Y., USA.
Icahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD) in the USA and worldwide, contributing to significant morbidity and mortality in diabetic patients. A genetic factor for the development of DN is strongly implicated, as only one third of diabetic patients eventually develop kidney disease. Growing evidence also supports an important role of epigenetic modifications in DN. SUMMARY: Multiple studies have been performed to identify risk genes and loci associated with DN. So far, only several genes and loci have been identified, none of which showed a strong association with DN. Therefore, a better study design with a larger sample size to identify rare variants and a clinically defined patient population to identify genes and loci associated with progressive DN are still needed. In addition to genetic factors, epigenetic modifications, such as DNA methylation, histone modifications and microRNAs, also play a major role in the pathogenesis of DN through a second layer of gene regulation. Although a major progress has been made in this field, epigenetic studies in DN are still in the early phase and have been limited mostly due to the heterogeneity of kidney tissue samples with multiple cells. However, rapid development of high-throughput genome-wide techniques will help us to better identify genetic variants and epigenetic changes in DN. KEY MESSAGE: Understanding of genetic and epigenetic changes in DN is needed for the development of new biomarkers and better drug targets against DN. Summarized in this review are important recent findings on genetic and epigenetic studies in the field of DN.

Indexed as

Diabetic nephropathyEnd-stage renal diseaseEpigeneticsGenetics

Identifiers

PMID27536664
PMCPMC4934801
OpenAlexW1992779719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.